NO20052426L - Fremgangsmater for vaksinasjon mot malaria - Google Patents

Fremgangsmater for vaksinasjon mot malaria

Info

Publication number
NO20052426L
NO20052426L NO20052426A NO20052426A NO20052426L NO 20052426 L NO20052426 L NO 20052426L NO 20052426 A NO20052426 A NO 20052426A NO 20052426 A NO20052426 A NO 20052426A NO 20052426 L NO20052426 L NO 20052426L
Authority
NO
Norway
Prior art keywords
methods
against malaria
vaccination against
based vaccine
protein
Prior art date
Application number
NO20052426A
Other languages
English (en)
Other versions
NO20052426D0 (no
Inventor
Joseph Cohen
Stephen L Hoffman
Ruobing Wang
Judith E Epstein
Original Assignee
Us Navy Naval Med Res Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Navy Naval Med Res Ct filed Critical Us Navy Naval Med Res Ct
Publication of NO20052426L publication Critical patent/NO20052426L/no
Publication of NO20052426D0 publication Critical patent/NO20052426D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen angår fremgangsmåter for beskyttelse mot malariainfeksjon ved vaksinasjon. Fremgangsmåten ifølge oppfinnelsen innbefatter å prime en antimalaria immunreaksjon med en DNA-basert vaksine og forsterke reaksjonen med en proteinbasert vaksine. Fremgangsmåten ifølge oppfinnelsen angår også en utvidelse av den resulterende i mmunreaksjonen ved en forsterkning med en proteinbasert vaksine.
NO20052426A 2002-10-23 2005-05-19 Fremgangsmater for vaksinasjon mot malaria NO20052426D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42026502P 2002-10-23 2002-10-23
US44702603P 2003-02-13 2003-02-13
PCT/US2003/033462 WO2004037189A2 (en) 2002-10-23 2003-10-22 Methods for vaccinating against malaria

Publications (2)

Publication Number Publication Date
NO20052426L true NO20052426L (no) 2005-05-19
NO20052426D0 NO20052426D0 (no) 2005-05-19

Family

ID=32179789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052426A NO20052426D0 (no) 2002-10-23 2005-05-19 Fremgangsmater for vaksinasjon mot malaria

Country Status (11)

Country Link
US (1) US8232255B2 (no)
EP (2) EP2277533B1 (no)
JP (2) JP5404990B2 (no)
AU (2) AU2003285932A1 (no)
CA (1) CA2502268A1 (no)
ES (1) ES2594758T3 (no)
NO (1) NO20052426D0 (no)
NZ (1) NZ539509A (no)
PL (1) PL376792A1 (no)
RU (1) RU2356577C9 (no)
WO (1) WO2004037189A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP2277533B1 (en) * 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methods for vaccinating against malaria
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CA2657353A1 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
US8400408B2 (en) * 2007-06-13 2013-03-19 Apple Inc. Touch screens with transparent conductive material resistors
AU2008288508B2 (en) 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
CA2707245A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccine
CN101969991A (zh) * 2008-01-18 2011-02-09 Aeras全球Tb疫苗基金会 可诱导细胞介导免疫的疟疾疫苗组合物和组分
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
EA023897B1 (ru) * 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
US20110117120A1 (en) * 2009-11-13 2011-05-19 Martha Sedegah Plasmodium falciparum HLA class I restricted T-cell epitopes
MX354752B (es) * 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
US9115205B2 (en) 2010-10-18 2015-08-25 The United States Of America, As Represented By The Secretary Of The Army Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US20150359869A1 (en) * 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2016059911A1 (ja) * 2014-10-17 2016-04-21 国立大学法人金沢大学 マラリアワクチン
US11065320B2 (en) 2016-04-12 2021-07-20 Oxford University Innovation Limited Prime target
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン
US12186380B2 (en) * 2017-05-24 2025-01-07 Ekkehard Werner Plasmodium falciparum and Plasmodium vivax vaccine
EP3704139A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
EP3704256A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
SG11202003200VA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
JP7366014B2 (ja) 2017-10-31 2023-10-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2123612C (en) 1991-11-16 2002-06-25 Michel De Wilde Hybrid protein between cs from plasmodium and h bsag
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
US5928902A (en) 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JP3967769B2 (ja) 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
RU2178710C1 (ru) * 2001-02-08 2002-01-27 Кожемякин Леонид Андреевич Индивидуальные вещества, полученные на основе химического взаимодействия дисульфидсодержащих пептидов с производными пуриновых или пиримидиновых оснований, фармацевтические композиции и препараты на их основе, способы их применения для лечения инфекционных заболеваний и профилактики осложнений
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
EP2277533B1 (en) * 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methods for vaccinating against malaria
US20050208078A1 (en) * 2003-11-20 2005-09-22 Hoffman Stephen L Methods for the prevention of malaria

Also Published As

Publication number Publication date
US8232255B2 (en) 2012-07-31
US20060188527A1 (en) 2006-08-24
JP5404990B2 (ja) 2014-02-05
WO2004037189A3 (en) 2004-10-21
EP2277533A3 (en) 2012-03-07
JP2006512405A (ja) 2006-04-13
WO2004037189A2 (en) 2004-05-06
EP2277533A2 (en) 2011-01-26
AU2010200177A1 (en) 2010-02-04
AU2003285932A1 (en) 2004-05-13
RU2356577C2 (ru) 2009-05-27
RU2005115837A (ru) 2006-01-20
ES2594758T3 (es) 2016-12-22
CA2502268A1 (en) 2004-05-06
EP2277533B1 (en) 2016-07-20
NO20052426D0 (no) 2005-05-19
PL376792A1 (pl) 2006-01-09
EP1569515A4 (en) 2006-04-26
EP1569515A2 (en) 2005-09-07
RU2356577C9 (ru) 2009-08-10
NZ539509A (en) 2008-05-30
JP2011068671A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2004037189A3 (en) Methods for vaccinating against malaria
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
DK1216053T3 (da) Influenzavaccine
NO20051469L (no) Immunstimulerende nukleinsyrer.
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2004098491A3 (en) METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
NO20024246L (no) Endret stamme av det modifiserte vacciniaviruset (Ankara MVA)
AU4358701A (en) Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
AU2021238777A8 (en) Modified mRNAs for vaccine development
NO20090178L (no) Vaksiner for malaria
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2022137128A3 (en) Self-amplifying messenger rna
WO2003004683A3 (en) Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses
NO20055857L (no) Materialer og fremgangsmater til immunisering mot FIV-infeksjon
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
WO2003103570A3 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
WO2005027844A3 (en) Dna vaccine compositions and methods of use
DK1554383T3 (da) Rekombinante MVA-stammer som potentieller vacciner mod P. falciparum-malaria
EA200400997A1 (ru) Способ, обеспечивающий профилактику туберкулёза у вич-положительных индивидов
WO2006113835A3 (en) Method of stimulating immune response in certain individuals
WO2004046168A3 (en) Recombinant hiv-1 subclass d envelope glycoproteins
DK1204421T3 (da) Stressprotein-peptidkomplekser som vacciner mod intracellulære patogener

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application